Aachen, North Rhine-Westphalia, Germany
Co-Founder & CFO at BioThrust. We at BioThrust develop a bionic bioreactor to enable efficient and scalable stem cell manufacturing. Previous engagament as Strategy Consultant at Oliver Wyman with Bachelor's and Master's Degree in Business and Management from WHU - Otto Beisheim School of Management. Strong interest in Entrepreneurship, Strategy and Innovation. Very analytical, structured and result-driven thinking combined with strong communication and interpersonal skills.
Co-Founder & CFO at the Deep Tech Start-up BioThrust. We at BioThrust develop a bionic bioreactor to enable efficient and scalable stem cell manufacturing. One of our unique innovations is the complete bubble-free aeration of bioreactors achieving a significant process yield increase. By efficiently scaling the cell cultivation process, we want to contribute to affordable stem cell therapies as well as driving progress in other sectors like clean meat and synthetic biologics.
-Peer-reviewed publications in the A-ranked Journal of Business Venturing and B-ranked Schmalenbach Journal of Business Research -Research on entrepreneurial empathy, crowdfunding and entrepreneurship during crises as part of the emergenCITY program -Joint article on the potential of crowdfunding for alleviating the consequences of the COVID-19 pandemic together with the Fraunhofer IMW
-Intern at the FINANCE 4 DB department of the Deutsche Bahn AG (Digital team of the corporate finance function) -Master Thesis on "Application of Digital Technologies to the Purchase-to-Pay (P2P) Process at Deutsche Bahn AG" -Analysis of current process including the creation of a holistic process map -Research and selection of most important digital technologies -Development of use cases for these technologies based on own hypotheses and interviews with P2P as well as technology experts
Life Science Division -Development of a pricing strategy for a leading pharmaceutical producer of ophthalmic products concerning the launch of two new drugs in the EU -Execution of a NPV calculation including the simulation of multiple scenarios to develop a final launch strategy -Participation in an update of the international price referencing rules library for pharmaceuticals in 33 countries